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Summary
Platelet aggregation requires activation of the αIIbβ3 integrin, an event regulated by the integrin
cytoplasmic tails. CIB1 binds to the cytoplasmic tail of the integrin αIIb subunit. Previous
overexpression and knockdown studies in murine megakaryocytes demonstrated that CIB1 inhibits
integrin αIIbβ3 activation. Here we analyzed Cib1−/− mice to determine the function of CIB1 in
platelets in vitro and in vivo. We found that although these mice had no overt platelet phenotype,
mRNA level of CIB1 homolog CIB3 was increased in Cib1−/− megakaryocytes. In vitro binding
experiments showed that recombinant CIB1, -2 and -3 bound specifically to an αIIb cytoplasmic tail
peptide. Subsequent protein modeling experiments indicated that CIBs 1–3 each have a highly
conserved hydrophobic binding pocket. Therefore, the potential exists for compensation for the loss
of CIB1 by these CIB family members, thereby preventing pathologic thrombus formation in
Cib1−/− mice.
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Introduction
Platelets respond to blood vessel injury to prevent further blood loss and restore vascular
integrity. They become activated at the site of vascular injury by newly exposed extracellular
matrix proteins (ECM) and secreted soluble agonists. Platelet activation promotes binding of
soluble and matrix adhesive proteins to activated surface receptors. The interaction of platelets
Address correspondence to: Leslie V. Parise, Dept. of Biochemistry and Biophysics, CB# 7260, The University of North Carolina, Chapel
Hill, NC, 27599. Tel.: 919-966-2238; Fax: 919-966-2852; Email: parise@med.unc.edu.
*Both authors contributed equally to this work.
NIH Public Access
Author Manuscript
Thromb Haemost. Author manuscript; available in PMC 2009 November 2.
Published in final edited form as:













with soluble proteins such as fibrinogen initiates platelet aggregation, whereas platelet
interaction with ECM proteins such as collagen allows both platelet adhesion and thrombus
generation.
Integrins are heterodimeric adhesion receptors that undergo conformational changes upon
agonist stimulation, resulting in increased ligand affinity. This process is termed inside-out
signaling (1). The most abundant integrin on the platelet surface is αIIbβ3. Active integrin
αIIbβ3 initiates and propagates the formation of platelet aggregates by binding to fibrinogen.
Although fibrinogen is the primary ligand for αIIbβ3, the activated integrin also binds other
extracellular proteins such as fibronectin, von Willebrand factor and vitronectin to support
platelet adhesion to the blood vessel wall (2;3). Since uncontrolled activation of integrin
αIIbβ3 can cause pathologic thrombus formation, precise regulation of the integrin is critical
for haemostasis (4).
CIB1 (CIB, calmyrin, and KIP1) was identified in a yeast-two hybrid screen to identify binding
partners for the integrin αIIb cytoplasmic tail (5). CIB1 is a widely expressed protein that
contains two calcium binding and two non-calcium binding EF hands (6;7). CIB1 interacts
with a number of serine/threonine kinases such as DNA-dependent protein kinase (8), polo-
like kinases Fnk and Snk (9), and PAK1 (10), as well as presenilin 2 (11), FAK(12) and the
InsP3 receptor (13). Recent in vivo studies demonstrate that CIB1 also plays a role in
pathological forms of angiogenesis (14) and is essential for spermatogenesis (15).
Previously, the function of CIB1 relative to αIIbβ3 was explored by acutely overexpressing
and knocking down the protein in murine megakaryocytes. These studies implicated CIB1 as
a negative regulator of agonist-induced αIIbβ3 activation (16). In separate studies where CIB1
function was also rapidly blocked by use of a CIB1 antibody, it was found that CIB1 binding
to αIIbβ3 is necessary for proper spreading on immobilized fibrinogen (17). Taken together
these studies imply that acute alterations in CIB1 protein misregulate αIIbβ3 function.
To more fully characterize the role of CIB1 in platelets, we asked if the chronic loss of CIB1,
via a CIB1 knockout mouse, would result the same phenotype as acutely altered CIB1. While
we hypothesized that loss of CIB1 would result in increased agonist-induced activation of
integrin αIIbβ3 and hyper-activatable platelets, the Cib1−/− mice did not display any overt
defect in platelet function. These results suggest that either CIB1 does not regulate the platelet
functions tested or that developmental compensation has occurred. In this regard, mRNA
expression for the CIB1 homolog CIB3 is increased in cultured megakaryocytes isolated from
the Cib1−/− mice. This protein may have a redundant or overlapping function in αIIbβ3
regulation and may compensate for the lack of CIB1. To test this, we produced recombinant
CIB1, -2 and -3 and compared their ability to bind to the αIIb cytoplasmic tail.
Materials and methods
Mice
Cib1−/− mice were previously generated in our lab as described by Yuan et al. (15). All mouse
experiments were performed in accordance with national guidelines and regulations and were
approved by the UNC Institutional Animal Care and Use Committee (IACUC). Mice used in
these experiments were backcrossed 10 generations to the C57BL/6 background.
Platelet isolation
Mice were euthanized by CO2. Blood was drawn by cardiac puncture into Eppendorf tubes
containing saline and ACD (85 mM sodium citrate, 111 mM glucose and 71 mM citric acid)
with 0.1 µM PGE1 (Sigma). To separate blood cells, whole blood was centrifuged for 10 min
at 250 × g. Platelet rich plasma (PRP) was removed and the remaining blood was washed with
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ACD/saline/PGE1 solution, centrifuged and PRP collected. PRP was pooled for each mouse
and centrifuged at 400 × g for 15 min. Platelet poor plasma (PPP) was discarded, and the platelet
pellet resuspended in warmed (37°C) CGS buffer (13 mM sodium citrate, 30 mM glucose and
120 mM NaCl) containing 10 U/ml apyrase (Sigma). Resuspended platelets were incubated at
37°C for 20 min before being centrifuged at 500 × g for 15 min. The platelet pellet was
resuspended in 0.5 ml modified HEPES-Tyrodes buffer (12 mM NaHCO3, 138 mM NaCl, 5.5
mM glucose, 2.9 mM KCl, 10mM HEPES containing 0.1% BSA, 1mM CaCl2, 1mM MgCl2
at pH 7.4). Platelets were allowed to rest for 1 h at room temperature (RT) before assaying.
Electron Microscopy
PRP was isolated as above and centrifuged at 400 × g for 15 min. PPP was removed and the
platelet pellet was fixed by the addition of 2% glutaraldehyde in 0.1 M sodium cacodylate
buffer pH 7.4 (all buffers provided by UNC Microscopy Services Laboratory). After 2 h at RT,
the glutaraldehyde solution was removed, the pellet washed with cacodylate buffer and fixed
in potassium ferrocyanide-reduced osmium tetroxide for 1 h at RT. The pellet was dried with
ethanol and embedded in PolyBed 812 epoxy resin (Polysciences, Inc., Warrington, PA, USA).
Sections of the pellet (70 nm thick) were mounted on copper grids and stained with 4.0% uranyl
acetate and 0.4% lead citrate. Sections were observed with a LEO EM 910 transmission electron
microscope (LEO Electron Microscopy, Inc., New York, NY, USA) using an accelerating
voltage of 80 kV. Platelet granules were scored for two mice of each genotype, and a minimum
of 45 platelets were counted per genotype.
Platelet spreading
Glass coverslips were coated with 1% BSA (Serologicals Protein Inc.) or 100 µg/ml fibrinogen
(Calbiochem). Platelets were isolated and washed as above and resuspended in Tyrodes-
HEPES buffer to 1 × 107 plts/ml. Precoated coverslips were washed twice with Tyrodes-
HEPES buffer and 100 µl platelets were added and incubated for 1 h at 37°C. Coverslips were
aspirated to remove unattached cells and remaining cells were fixed with 1.0%
paraformaldehyde for 15 min at RT. Coverslips were washed twice and permeablized with
0.2% Triton-PBS for 30 seconds and washed three times with Tyrodes-HEPES. For staining,
coverslips were incubated in the dark with 1:1,000 phallodin-488 (Molecular Probes) for 30
min. Coverslips were rinsed and adhered to slides with FlouroSave (Calbiochem).
Flow cytometry
Washed platelets were incubated with a FITC-labeled antibody for 15 min (JON/A,
glycoprotein (GP) 1b and respective IgG controls, EMFRET, Germany) or 30 min (αIIb or
α2 and respective IgG controls, BD BIOSCIENCE) at RT. For αIIbβ3 activation experiments,
agonist (0.1 U thrombin or 10 µM ADP final concentrations) was added simultaneously with
the antibody. P-selectin expressed on the platelet surface was measured in whole blood using
a FITC-labeled P-selectin antibody (EMFRET, Germany). Whole blood samples were
prepared as described by manufacturer’s instructions. P-selectin expression was induced by
activation 0.25 mM PAR4 peptide (thrombin receptor activating peptide, AYPGKF,
synthesized by the UNC Protein Chemistry Core) or 100 µM ADP, as a negative control, as
determined by the manufacturer’s protocol (EMFRET). After incubating, all samples were
diluted with Tyrodes-HEPES and analyzed on a BD FACSCanto flow cytometer (BD
Biosciences) at a low flow rate. Surface expression data were normalized by dividing the mean
fluorescent intensity of the antibody by the control IgG intensity. Activation data were
normalized by dividing the agonist stimulated mean fluorescence by that of the unstimulated
cells.
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Platelets were isolated as above and diluted into Tyrodes-HEPES buffer to 1.5 × 108 plts/ml.
Platelets were aliquoted into aggregation tubes and incubated at 37° C for 15 min before the
addition of agonist, 0.1 mM PAR4 peptide (AYPGKF, synthesized at UNC Protein Chemistry
Core) or 5 µM ADP. Traces were recorded for 5–6 min in a CHRONO-LOG Corporation
Model 700 Aggregometer. Aggregometry data were analyzed by Aggrolink8 software
(CHRONO-LOG).
Bleeding times assay
Mice were anesthetized with isoflurane and given an intraperitoneal injection of 10 µl/g mouse
of ketamine hydrochloride (75µg/kg). Mouse tails were cut at 4mm from the tip and placed
into Phosphate-buffered saline (PBS) warmed to 37°C. Time was recorded until the stream of
blood fully stopped. Mouse tails were cauterized after 15 min if bleeding did not stop.
Carotid artery thrombosis
Adult mice (24–34 g) were anesthetized with isoflurane and maintained under inhaled
anesthesia at a temperature of 36–37.5°C. The carotid artery was exposed and rinsed with
saline. To measure baseline flow rate, a Doppler flow probe (#0.5VB307, Transonic Systems
Inc) connected to a flow meter (T106, Transonic Systems Inc) was placed on the blood vessel
and both were covered with a lubricating jelly. After baseline was determined, the artery was
rinsed with saline and a 1 × 2 mm piece of Whatmann paper saturated with 20% ferric chloride
was placed on the vessel for 2 minutes. After 2 min the filter paper was removed from the
artery and replaced with lubricating jelly. Blood flow was measured until the vessel occluded.
Western blot analysis
Washed platelets were lysed in modified CHAPS buffer (20 mM HEPES, pH 7.4, 150 mM
NaCl , 10 mM CHAPS , 50 mM NaF , 10 mM β-glycerophosphate, 1:100 concentration
Protease Inhibitors Cocktail Set III (Calbiochem), 1 mM CaCl2 and 1 mM MgCl2) on ice for
30 min. Lysates were collected after a 10 min centrifugation and the protein concentration was
quantified by the BCA protein assay (Pierce). Protein samples were separated by SDS-PAGE,
transferred to a PVDF membrane and subjected to Western blotting. A CIB1 chicken polyclonal
antibody was used to detect mouse CIB1. The antibody against GAPDH was from Santa Cruz
Biotechnology.
Primary megakaryocyte culture
Murine bone marrow-derived megakaryocytes were cultured as previously described (18).
Briefly, bone marrow cells were flushed and isolated from tibias and femurs of mice and
cultured for three days in medium containing Interleukin (IL)-6, IL-11 and thrombopoietin
(PeproTech).
Quantitative reverse transcriptase-PCR
Megakaryocytes derived from bone marrow stem cells were isolated as above. RNA was
isolated with the Qiagen RNA Isolation kit. Isolated RNA was transcribed into cDNA using
Applied Biosystems’ High-Capacity Reverse Transcription Kit. Primers for Cib1, Cib2, Cib3,
Cib4 and Gapdh were purchased from SuperArray. Sequences were proprietary, reference
positions for partial product sequence amplified by primers, relative to NCBI RefSeq entry
provided by SuperArray; Cib1 260–278 (RefSeq Accession# NM_011870), Cib2 590–609
(RefSeq Accession# NM_019686), Cib3 326–344 (RefSeq Accession# XM_356089.4), Cib4
271–291 (RefSeq Accession# XM_131990.3) and Gapdh 962–983 (RefSeq Accession#
NM_008084.2). SYBR Green PCR Mastermix was also from SuperArray and manufacturer’s
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protocol was followed. Real time qPCR reactions were run on Applied Biosystems Instruments
Prism 7900HT Sequence Detection System using the standard 1 cycle at 95° C for 10 min and
40 cycles of 95° C for 15 s then 60° C for 1 min. Fold change in gene expression was calculated
using the ΔΔCt method(19;20).
Protein purification
PCR primers were designed to amplify Cib1-3 mRNAs isolated from murine megakaryocytes.
PCR products of Cib1, -2 and -3 were ligated into the pEXP5-NT/TOPO vector (Invitrogen)
and correct sequences were verified. BL21 bacteria (Stratagene) were transformed with
pEXP5-NT/TOPO vectors, grown at 37°C and induced with isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 4 h at 30°C to produce the desired proteins. pEXT5-NT/
TOPO calmodulin-like 3 from Invitrogen was used as a control. Bacteria producing CIB1,
CIB2 and calmodulin-like 3 were lysed by sonication and centrifuged at 10,000 × g for 20 min.
Supernatant was run on an FPLC-nickel column to purify the protein. Since CIB3 was
insoluble, the bacteria producing CIB3 were lysed and denatured in buffer containing 8 M urea
(Sigma), 100 mM NaH2PO4 (Mallinckrodt) and 10 mM Tris-Cl (Fisher) at pH of 8.0. Lysate
was centrifuged to remove cellular debris and Ni-NTA slurry (Qiagen) was added to the
supernatant and incubated at RT for 1 h with shaking. The lysate-resin mixture was loaded
onto a column and flow-through was removed. The column was washed twice with buffer
containing 8 M urea, 100 mM NaH2PO4 and 10 mM Tris-Cl at pH 6.3. Protein was eluted with
buffer containing 8 M urea, 100 mM NaH2PO4 and 10 mM Tris-Cl at pH 5.9. Eluate was
dialyzed into 8 M urea, 200 mM NaCl and 50mM Tris pH 8.0 at 4° C. After 4 h, an equal
volume of buffer containing 200 mM NaCl and 50 mM Tris pH 8.0 with 2 mM dithiothreitol
(DTT, ROCHE) was added to dilute the urea and left to dialyze overnight. Buffer was then
exchanged with 2 M urea, 200 mM NaCl, 50 mM Tris pH 8.0 and 2 mM DTT to continue
dialyzing and allow protein refolding. This process continued every 8 h until the urea was fully
removed. The DTT was dialyzed out of solution by 200 mM NaCl, 50 mM Tris pH 7.5. The
protein was dialyzed into a final buffer containing 20 mM Tris pH 7.5, 300 µM CaCl2 and 85
mm NaCl.
ELISA
An αIIb cytoplasmic tail (CT) peptide (sequence LVLAMWKAGFFKRNR synthesized by
Genscript Corporation) or a scrambled control peptide (sequence
DKFGRPPKVENEELEDRGEF, synthesized by UNC Protein Chemistry Core Facility) was
coated on a microtiter plate (NUNC) overnight at 4°C at a concentration of 75 µg/ml. BSA
(3%) was used to block non-specific interactions in peptide-coated and non-coated wells.
Proteins were diluted in 50 mM HEPES, 150 mM NaCl with 0.1 mM CaCl2 and MgCl2 pH
7.4 to a range of 0.5 µg/ml to 20 µg/ml and were allowed to adhere to the plate for 1 h at RT.
The samples were removed, and the plate was washed three times with 0.5% TBS-Tween, pH
7.4. A primary anti-HIS antibody was added and incubated for 1 h at RT. The antibody was
removed and the plate was washed as above. An anti-rabbit-HRP antibody was then added to
the microtiter place for 1 h at RT. The secondary antibody was removed, and the plate was
washed as above. Binding was visualized by a color reaction with chromogenic substrate OPD
Sigma Fast Tablets (Sigma) for 10 min at RT in the dark. The reaction was stopped with 4N
H2SO4 and the plate was read at 490 nm in Medical Devices SpectraMax Plus plate reader.
For competition binding assays, 5 µg/ml of CIB1, -2 and -3 were incubated with increasing
concentrations (1.0–100 µg/ml) of soluble αIIb peptide. Each sample and concentration was
performed in triplicate for all ELISAs.
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CIB homology and model analysis
CIB homologs in the UniProt database (21) were identified using sequence similarity BLAST
searches (22) of the human CIB1 protein. We used ClustalX (23) to generate a multiple
sequence alignment of the three human CIB homologs (CIB1 (Q99828), CIB2 (O75838), CIB3
(Q96Q77)), and homologs of the fruitfly and worm CIB gene (D. melanogaster (Q9W2Q5),
D. pseudoobscura (Q28ZR4), C. elegans (Q93640)). We then mapped highly conserved
residue positions onto the crystallographic structure of human CIB1 (PDB ID 1XO5 (6)).
Statistical analysis
All values are presented as the mean ± standard error of the mean (SEM). A t-test was used to
evaluate statistical significance. P-values less than 0.05 were considered statistically
significant. N ≥ 3 for all experiments.
Results
Platelet function is normal in Cib1−/− mice
We first confirmed that CIB1 was absent in the Cib1−/− platelets by Western blotting (Fig.
1A). The overall morphology of the platelets by transmission electron microscopy appeared
normal; platelet shape and organelles were similar in both genotypes (Fig. 1B, C). The number
of α- and dense granules per platelet were scored. There was no statistical difference in the
number of either dense or α-granules in the Cib1−/− versus control platelets (Fig 1C). Flow
cytometry with antibodies specific to integrins αIIbβ3 and α2β1, and glycoprotein (GP) Ib
indicated that there were no statistically significant differences detected in the expression levels
of these receptors on platelets isolated from the Cib1+/+ and Cib1−/− mice (Fig. 1D). These
results thereby assure that any difference displayed in our αIIbβ3 functional studies was not
due to a change in surface expression of αIIbβ3.
To examine potential differences in αIIbβ3 activation between Cib1+/+ and Cib1−/− mice, we
measured binding of an activation-specific antibody binding (JON/A) to αIIbβ3 in resting or
agonist stimulated platelets by flow cytometry. Basal αIIbβ3 activity in resting platelets was
comparable in Cib1−/− and Cib1+/+ mice (measured by the binding of unstimulated cells to the
JON/A antibody). We also found no significant difference in the ability of Cib1−/− platelets
to bind JON/A in response to a relatively weak agonist (10 µM ADP), or strong agonist (0. 1
U thrombin) versus platelets isolated from Cib1+/+ littermate controls (Fig. 2A). We then used
platelet aggregation to evaluate αIIbβ3 activation. We found that Cib1−/− platelets aggregate
in a similar manner as Cib1+/+ platelets when stimulated by agonist 0.1 mM PAR4 peptide or
5 µM ADP (Fig. 2B). (As we did not add exogenous fibrinogen to our aggregation experiments,
5 µM ADP was the lowest concentration of agonist that could provide a consistent aggregation
response).
Platelet activation leads to exposure of P-selectin on the platelet surface; therefore we used
flow cytometry to examine any potential changes in P-selectin exposure. We found similar
surface expression levels of P-selectin on resting platelets from Cib1+/+ mice and Cib1−/−
mice, and on platelets activated by 100 µM ADP or 0.25 mM PAR4 (Fig. 2C). P-selectin surface
expression and agonist-induced α-granule release did not appear to be affected by the loss of
CIB1. These results imply that the absence of CIB1 does not alter integrin αIIbβ3 expression
or activation.
Acute blockade of CIB1 in platelets inhibits platelet spreading on immobilized fibrinogen
(12;17). We therefore tested platelets from the Cib1−/− mice to determine the effect of the loss
of CIB1 on platelet spreading, but found no difference between size and overall cell number
of platelets adhered to fibrinogen in the presence or absence of ADP (Fig. 3A–C). Platelet
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spreading was also similar between the two genotypes after PAR4 stimulation, or on collagen
in the absence or presence of ADP (data not shown). Therefore, outside-in signaling as
measured by platelet spreading appears to be normal in the Cib1−/− deficient mice.
In vivo experiments
We then used whole animal models to determine the response of Cib1−/− mice to blood vessel
injury. A bleeding time assay measures the time necessary for bleeding to stop after the removal
of a small portion of the mouse’s tail (24). We found no statistically significant difference in
the average bleeding time for Cib1−/− versus Cib1+/+ mice (Fig. 4A). The ferric chloride injury
model is frequently used for assessing in vivo responses to injury to the blood vessel
endothelium (25). Ferric chloride causes tissue damage by iron-mediated chemical oxidation,
resulting in separation of endothelial cell junctions and exposure of type I collagen (26;27).
To determine the role of CIB1 in thrombus formation upon vascular injury, ferric chloride was
placed on the carotid artery to expose the underlying ECM (27). Time to full vessel occlusion
by a stable thrombus was similar between the Cib1+/+ and Cib1−/− mice (Fig. 4B). Thus,
Cib1−/− mice exhibit no discernible differences in thrombus formation or stability leading to
vessel occlusion and blood clotting in vivo as measured by these assays.
CIB family gene Cib3 is over-expressed in Cib1−/− primary megakaryocytes
Our previous studies involving the acute modulation of CIB1 levels in megakaryocytes showed
that CIB1 is an endogenous inhibitor of αIIbβ3 activation (16). Here we tested αIIbβ3 activation
in megakaryocytes from Cib1−/− mice to determine whether chronic loss of CIB1 has a similar
phenotype to the acute megakaryocyte studies (16). However, we found that megakaryocytes
differentiated in culture from the bone marrow stem cells of Cib1−/− mice bound fibrinogen
in a similar manner as those from Cib1+/+ mice. Specifically, both genotypes had similar levels
of fibrinogen binding under basal conditions and upon stimulation with agonist PAR4 (Fig.
5A). This result models our Cib1−/− and Cib1+/+ platelet data, and are in contrast to results
obtained with short term, direct protein or genetic manipulations (12;16;17;28).
Since we did not see a change in αIIbβ3 activation in Cib1−/− mouse platelets or
megakaryocytes, we considered the possibility of functional compensation by other CIB family
members, as the chronic loss of CIB1 could alter the expression of other genes. Genes of human
homologs Cib2, Cib3 and Cib4 have been reported (6) and genes of mouse Cib2–4 can be
identified in the mouse gene database. The identified and predicted CIB protein transcripts are
highly homologous between human and mouse. CIB1 is 94% identical while CIB2, CIB3 and
CIB4 are 97%, 94% and 91% identical, respectively, as determined by BLAST analysis.
Therefore, we examined the expression of these mouse genes using real-time qPCR with
mRNA derived from cultured murine megakaryocytes. We found increased Cib3 mRNA
expression in the Cib1−/− bone marrow-derived megakaryocytes while Cib2 message levels
remained constant between Cib1+/+ and Cib1−/− megakaryocytes (Fig. 4B). Endothelial cell
function is affected by the loss of CIB1(14); therefore we examined the relative mRNA
expression levels of Cib2 and Cib3 in Cib1−/− endothelial cells to that in Cib1+/+ endothelial
cells. Unlike megakaryocytes, Cib2 and Cib3 mRNA expression is not elevated in Cib1−/−
endothelial cells compared to Cib1+/+ cells (Fig. 5B). Cib4 was excluded from further studies
because only a very low level of Cib4 message (slightly above background) was detected in
both megakaryocytes and endothelial cells by reverse transcriptase-PCR and by qPCR in either
genotype (data not shown).
Since mRNA from the Cib1−/− megakaryocytes displayed a different expression pattern for
Cib3 relative to Cib1+/+ megakaryocytes, we further investigated the possibility of functional
compensation. We produced and purified recombinant CIB1, -2 and -3 proteins from bacterial
cultures to test the binding properties of CIB family proteins with integrin αIIb. It is currently
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unknown whether CIB2 or CIB3 is expressed in platelets. CIB2 protein expression has been
identified in HEK cells (29) but CIB3 protein remains to be examined or reported. Antibodies
that recognize mouse CIB2, -3, or -4 are not currently available. Nonetheless, we asked if
recombinant murine CIB2 and CIB3 could bind to αIIb. We immobilized an αIIb-cytoplasmic
tail (CT) peptide in microtiter wells, added increasing concentrations of recombinant CIB1,
-2, and -3 proteins and measured binding by ELISA (Fig. 6A). Interestingly, all three CIB
proteins bound to immobilized αIIb-CT peptide. However, none of the proteins bound to a
scrambled control peptide, thereby implicating a specific interaction between these CIB
proteins and αIIb (Fig. 6A). To further ensure the specificity of binding to the αIIb-CT peptide,
we added increasing concentrations of soluble αIIb peptide to compete with CIB protein
binding to immobilized peptide. Addition of this soluble peptide decreased the binding of CIB1,
-2 or -3 to immobilized peptide (Fig. 6B), reaffirming a specific interaction between the αIIb-
CT peptide and CIB proteins, whereas the soluble scrambled peptide did not interfere with CIB
protein binding (data not shown). These findings demonstrate that CIB2 and CIB3 can bind to
the cytoplasmic tail of αIIb in vitro and therefore have the potential to compensate for the loss
of CIB1.
Computer modeling of the CIB family
For insight into the potential mechanism of how CIB2 and/or CIB3 might compensate for the
loss of CIB1 in αIIbβ3 regulation, we performed computer modeling studies. We evaluated
CIB family homology by aligning the ancestral CIB protein from worm (Caenorhabditis
elegans) and fruit fly (Drosophila melanogaster) with the human CIB1-3 proteins. Highly
conserved residues are represented in purple and yellow while non-conserved residues are
represented in grey and orange (Fig. 7). The conservation is indicative of potential functionality
that existed in the CIB ancestor and that has been maintained in the CIB1-3 homologs (purple
and yellow residues Fig. 7).
Residues in CIB1 that are proposed to interact with αIIb based on previous studies and on the
crystal structure of CIB1 (5–7,30–32) were specifically compared to the corresponding
residues in CIB2 and CIB3. CIB residues hypothesized to form a hydrophobic binding pocket
for the αIIb tail are designated by yellow for conserved and orange for non-conserved residues
(Fig. 7A). Almost all of the residues in the hydrophobic binding pocket are highly conserved
between the three human CIB homologs and the worm and fruit fly CIB homolog, indicating
a potentially shared functional domain.
The C-terminus of CIB1 has been proposed to be displaced upon αIIb binding (32); therefore,
we also performed a modeling analysis with the C-terminus of CIB2 and CIB3 removed (Fig.
7B). The additional residues exposed in CIB2 and CIB3 were highly homologous to those
exposed in CIB1 upon C-terminal deletion (Fig. 7B). In addition, the length and depth of the
hydrophobic binding pocket was enlarged similarly between each CIB protein. This suggests
that all three CIB proteins may use the C-terminus to control binding specificity as proposed
by Yamniuk et al. 2006 (32) for CIB1.
Discussion
Activation and regulation of platelet integrin αIIbβ3 has been extensively studied, and much
is now known about how the integrin becomes activated (33–35); yet, the precise mechanisms
controlling activation and deactivation of the integrin and molecules involved are still under
investigation. Several intracellular binding partners of the integrin are known to regulate
αIIbβ3 activation (36). Interestingly, most of these regulatory proteins bind to the β3
cytoplasmic tail and not to αIIb (36). The αIIb subunit currently has only a handful of binding
partners, and there has been conflicting reports on the function of these proteins in αIIbβ3
activation (37–41). Previously we identified CIB1 in a screen for binding partners, and potential
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regulators of the αIIb cytoplasmic tail. Initial genetic studies of CIB1 function required a
megakaryocyte model because only platelets and megakaryocytes express the required
signaling machinery involved in integrin αIIbβ3 inside-out activation and platelets are not
amenable to direct genetic manipulation (42). For a more comprehensive understanding of the
role of CIB1 in the regulation of integrin αIIbβ3 activation, we created a Cib1−/− mouse and
studied the function of platelets and megakaryocytes derived from these mice. We found no
significant difference in the protein expression, basal activation or agonist-induced activation
of αIIbβ3, as measured by flow cytometry. There was also no significant difference in
aggregation or spreading between platelets from Cib1+/+ or Cib1−/− mice.
The lack of a phenotype in αIIbβ3 activation in Cib1−/− mice was unexpected because our
megakaryocyte studies and other independent studies in platelets (7;12;16;17;28;43)
demonstrated that CIB1 regulates αIIbβ3 activation and platelet spreading. One possible
explanation for the apparent lack of phenotype in the Cib1−/− platelets could be due to a
compensatory mechanism that occurred during mouse development. The most obvious
possibility would be compensation by another CIB family member. The idea of functional
compensation resulting in a limited phenotype is not novel. For example, Vav1 and Vav3 are
functionally redundant in their role of activating PLCγ2 (44) in platelets. Other proteins, when
knocked down or knocked out, also have not displayed the platelet phenotype predicted by
previous short term genetic manipulations (44–47). The discrepancies in our previous
megakaryocyte results and in vivo results may reflect fundamental differences in chronic
genetic mutations (knock-out or knock-in), which are subject to developmental compensation
compared to acute genetic mutations (knock-down or overexpression), which can reflect the
function of a protein in the absence of compensation. Both short and long term genetic
manipulations provide valuable information but the results should be only interpreted under
each experimental condition.
In real-time PCR experiments we detected an increase in the message of Cib3 while the message
of Cib2 did not change between Cib1+/+ and Cib1−/− in megakaryocytes. Therefore, the
potential binding of CIB2 and CIB3 to the αIIb tail was investigated. ELISA data indicated
that CIBs1-3 can all bind to the cytoplasmic tail of αIIb. The apparent CIB2/αIIb interaction
was unexpected since CIB2 did not bind αIIb in a yeast two-hybrid assay (16).
Sequence homology shows that human CIB2, CIB3 and CIB4 are 59%, 62% and 64%,
homologous to CIB1, respectively (6). Human CIBs show equivalent residues involved in the
structure of the hydrophobic binding pocket, i.e. the canonical αIIb binding site by sequence
alignment (6). Currently, only human CIB2 has been reported as a protein in the literature
(29); endogenous human or murine CIB3 and CIB4 proteins have not been identified to date.
The computer homology modeling analyses of CIB proteins provide insights into potentially
conserved αIIb binding domains in CIB1-3 that support our protein binding data. We observed
a highly conserved hydrophobic binding pocket in all CIB1-3 proteins. CIB1 is reported to
undergo displacement of its C-terminus upon αIIb binding, which increases the size of the
hydrophobic binding pocket (32). Virtual removal of the corresponding C-terminal residues in
CIB2 and CIB3 also led to an increase in the size of the hydrophobic binding pocket as revealed
by our modeling studies. The residues exposed by displacement of the tail were also highly
conserved between CIB1, -2 and -3. This theoretical structural change could potentially allow
CIB2 and CIB3 to share binding partners with CIB1, e.g. integrin αIIbβ3. Future studies of the
biophysical properties of the CIB family with isothermal titration calorimetry or other
approaches will further our understanding of the properties with which this family interacts
with αIIbβ3.
It will be interesting to determine if any other tissues or cell types in the Cib1−/− mice have
altered CIB family protein expression. It is known that the chronic loss of CIB1 affects
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spermatogenesis (15) and angiogenesis (14) in the Cib1−/− mice. This begs the question of why
some cell types or processes may have developed compensatory mechanisms, while other cells
have not. For example, endothelial cells isolated from the Cib1−/− mice do not have fully
functional compensatory mechanisms, as they have decreased migration in culture and in
vivo these mice have a defective pathological angiogenic response to ischemia (14). Also of
interest is the question of how many binding partners are shared by CIB1, -2 and -3? Since the
functional role of the CIB family in vivo has not been established, the development of
investigational tools such as expression plasmids and antibodies to other CIB family proteins
will aid the investigation of CIB protein function and regulation. RNAi will also be important
in acute knockdown studies to evaluate the activation potential of αIIbβ3 in megakaryocytes
from the Cib1−/− mouse with CIB3 acutely knocked down.
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Figure 1. Platelet morphology of Cib1−/− mice
A) CIB1 is absent in platelets isolated from the Cib1−/− mice. Platelet lysates from Cib1+/+,
Cib1+/− and Cib1−/− mice were subjected to Western blotting and CIB1 expression was
compared. GAPDH was used as a loading control. B) Resting platelet morphology is normal
when examined by electron microscopy. There was no significant difference in size, shape and
granule content (C) between Cib1+/+ and Cib1−/− platelets. Scale bar equals 0.2 µM. D) Surface
receptor expression on Cib1−/− platelets is similar to expression on Cib1+/+ platelets. To detect
surface receptor expression, washed platelets were incubated with FITC-〈IIb antibody, FITC-
〈2 antibody or FITC-IgG control for 30 min, or FITC-GP1b antibody or FITC-IgG for 15 min
at RT. Flow cytometry was used to determine mean fluorescence. Values were normalized and
presented as fold over IgG control (antibody/control) (N ≥ 9).
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Figure 2. Platelet function is unaffected by the loss of CIB1
A) Integrin 〈IIb®3 activation is normal when assessed by flow cytometry. Washed platelets
were incubated for 15 min with an 〈IIb®3 active conformation specific antibody (JON/A) or
IgG control. Basal expression was defined as JON/A binding over IgG control binding (JON/
A antibody/control antibody). Agonist-induced activation was measured by stimulating
platelets with either 10 µM ADP or 0.1 U thrombin (per 50 µl reaction) and expressed as the
increase in antibody binding in stimulated divided by nonstimulated platelets (N ≥ 4). B)
Platelet aggregation is normal in washed Cib1+/+ and Cib1−/− platelets. Washed platelets were
stimulated by 5 µm ADP (left) or 0.1 mM PAR4 peptide (right) and platelet aggregation traces
were recorded for 5 min. Representative traces are shown (N ≥ 2). C) Platelet P-selectin surface
expression is not affected by the loss of CIB1 as measured by flow cytometry. P-selectin was
expressed on the platelet surface at similar levels after agonist stimulation with 100 mM ADP
or 0.25 mM PAR4 peptide (N ≥ 3).
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Figure 3. Platelet spreading is normal in the chronic absence of CIB1
A) Platelets from Cib1+/+ and Cib1−/− mice adhered and spread similarly on immobilized BSA
or fibrinogen (fib). Cib1−/− platelets did not respond differently in the presence or absence 100
µM ADP compared to Cib1+/+ platelets. Platelets were allowed to spread for 60 min at 37°C.
Scale bar = 1 µm. Platelet size (B) and count (C) were analyzed by ImagePro software and
compared between Cib1+/+ and Cib1−/− . There was no significant difference between the two
genotypes (N ≥ 3).
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Figure 4. Platelet activation and thrombus formation are normal in Cib1−/− mice
A) Bleeding time assay was used to measure thrombus formation and stability in Cib1+/+ and
Cib1−/− by cutting the distal 4 mm portion of the tail and recording clotting time. Cib1−/− mice
had mildly prolonged bleeding time but the difference was not statistically significant from
Cib1+/+ (N ≥ 20 for each genotype). B) Carotid artery thrombosis model was also used to detect
differences in thrombus formation and stability. Ferric chloride (20%) saturated paper was
placed on the carotid artery to induce injury. Time necessary for full vessel occlusion was
recorded and graphed (N = 8 for each genotype).
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Figure 5. Megakaryocytes from Cib1−/− mice demonstrate variations in mRNA of CIB family
members
A) Activation of integrin αIIbβ3 on cultured bone marrow derived megakaryocytes was similar
between Cib1+/+ and Cib1−/− mice when measured by flow cytometry. Megakaryocytes were
stimulated with increasing concentrations of PAR4 peptide (0.5 mM and 1 mM) and binding
of Alexa-546 labeled fibrinogen was determined. Mean fluorescent intensities were normalized
by dividing the stimulated value by the unstimulated control (N = 3). B) Cib1−/− mice have
significantly increased CIB3 mRNA in megakaryocytes derived from bone marrow stem cells
as measured by quantitative PCR, while CIB2 retains the same level of expression as
Cib1+/+. Gapdh was the housekeeping gene used to normalize cycle threshold (CT) values.
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Fold values were defined using the ΔΔCt calculation (Livak et al., 2001; Schefe et al., 2006).
Fold value of 1 equates to no change in expression, while values above 1 equal increases in
message and values below 1 equal decreases in message expression relative to expression in
Cib1+/+ cells. Also expression of CIB2 and CIB3 mRNAs are different in Cib1−/− endothelial
cells versus megakaryocytes. (N for megakaryocytes ≥ 5 and N for endothelial cells = 20).
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Figure 6. CIB family members interact with integrin 〈IIb®3
A) CIB1-3 proteins bind to integrin 〈IIb peptide as measured by ELISA. Cytoplasmic tail
peptides of integrin subunit 〈IIb (〈IIb) or a scrambled control (scr) were immobilized and
increasing concentrations of recombinant CIB1, -2 or -3 were added to peptide- or BSA-coated
wells. Data graphed is a representative experiment of OD 490 (nm) values of peptide-coated
wells minus non-specific binding (N = 3). B) Soluble peptide competition ELISAs demonstrate
that the CIB1-3 interactions with 〈IIb peptide are specific. Increasing concentrations of soluble
〈IIb peptide were incubated with CIB1, -2, -3 or control protein, calmodulin-like 3, for 30 min.
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Samples were added to immobilized 〈IIb peptide or BSA coated wells. Data is presented as in
(B) (N = 3).
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Figure 7. Computer modeling of CIB family proteins reveals a highly conserved hydrophobic
binding pocket
A) Homology map of CIB proteins based on the ancestral CIB found in C. elegans. Grey
represents non-conserved residues, purple represents conserved residues, yellow represents
conserved residues in the hydrophobic binding pocket and orange represents non-conserved
residues in the hydrophobic binding pocket. B) Model of CIB after displacement of the C-
terminal tail. Molecular surfaces are represented as in (A).
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